Article Text

Download PDFPDF
Case report
Neuroendocrine tumour of urinary bladder: a rare case of aggressively behaving primary well-differentiated neuroendocrine tumour with review of literature
  1. Rohit Dadhwal1,
  2. Siddharth Jain1,
  3. Amlesh Seth1 and
  4. Chandra Shekhar Bal2
  1. 1 Urology, All India Institute of Medical Sciences, New Delhi, India
  2. 2 Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
  1. Correspondence to Dr Siddharth Jain; siddharthjainvmmc{at}gmail.com

Abstract

Neuroendocrine tumour (NET) of the urinary bladder (UB) is a rare entity and comprises of well-differentiated, small cell and large cell types. Small and large cell NET like that in lung and gastrointestinal tract have an aggressive nature and are considered high-grade disease. Well-differentiated NET has been thought to be localised and having a good prognosis. We report the first case of metastatic well-differentiated NET of the UB. Our case is a 44-year-old man with well-differentiated NET of UB presented with hepatic and peritoneal metastases on initial diagnosis. He was treated with metaiodobenzylguanidine (MIBG) therapy and had a modest survival of 16 months. The primary well-differentiated NETs can present as a metastatic disease with an aggressive nature. MIBG therapy can be considered as a useful option but overall prognosis is poor. Further research is needed for better understanding and better treatment protocol.

  • urological cancer
  • pathology
  • urology
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors RD worked up the patient from the beginning and was responsible for all investigations and patient well being in preoperative and postoperative period. SJ operated upon the patient and was following patient along with RD. AS was overall in charge and was looking after the patient in a very meticulous way. CSB was incharge of MIBG therapy and patient care when he recieved adjuvant therapy.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Next of kin consent obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.